An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
This study has been completed.
Sponsor:
Solvay Pharmaceuticals
Information provided by:
Solvay Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00335374
First received: June 8, 2006
Last updated: February 5, 2009
Last verified: February 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
Condition | Intervention | Phase |
---|---|---|
Early Stage Parkinson's Disease |
Drug: Pardoprunox |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial paroxysmal nonkinesigenic dyskinesia
Perry syndrome
MedlinePlus related topics:
Parkinson's Disease
U.S. FDA Resources
Further study details as provided by Solvay Pharmaceuticals:
Primary Outcome Measures:
- Safety: laboratory data, adverse events, vital signs, ECG [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- UPDRS parts 1, 2 and 3, CGI-severity, CGI-Improvement, PDQ-39 total score: all change from baseline [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Enrollment: | 202 |
Study Start Date: | August 2007 |
Study Completion Date: | November 2008 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1 |
Drug: Pardoprunox
12 -42 mg
|
Eligibility
Ages Eligible for Study: | 30 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients who have completed S308.3.003 trial
Exclusion Criteria:
- Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at end of the maintenance phase (visit M6, week 24) of study S308.3.003
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00335374
Show 75 Study Locations
Show 75 Study Locations
Sponsors and Collaborators
Solvay Pharmaceuticals
Investigators
Study Director: | Global Clinical Director Solvay | Solvay Pharmaceuticals |
More Information
No publications provided
Keywords provided by Solvay Pharmaceuticals:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
No publications provided
Responsible Party: | Ellen van Kleef, Solvay Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00335374 History of Changes |
Other Study ID Numbers: | S308.3.008, 2006-000859-18 |
Study First Received: | June 8, 2006 |
Last Updated: | February 5, 2009 |
Health Authority: | United States: Food and Drug Administration Australia: Department of Health and Ageing Therapeutic Goods Administration Czech Republic: State Institute for Drug Control Estonia: The State Agency of Medicine France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Germany: Paul-Ehrlich-Institut India: Ministry of Health Italy: The Italian Medicines Agency Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) Poland: Ministry of Health Portugal: National Pharmacy and Medicines Institute South Africa: Medicines Control Council Spain: Spanish Agency of Medicines Taiwan: Department of Health Thailand: Food and Drug Administration United Kingdom: Medicines and Healthcare Products Regulatory Agency Lithuania: State Medicine Control Agency - Ministry of Health Malaysia: Ministry of Health |
Keywords provided by Solvay Pharmaceuticals:
Parkinson's disease |
Additional relevant MeSH terms:
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |
ClinicalTrials.gov processed this record on October 16, 2012